New therapeutic approaches in breast cancer

Maturitas ◽  
2011 ◽  
Vol 68 (2) ◽  
pp. 121-128 ◽  
Author(s):  
Eleri Davies ◽  
Stephen Hiscox
Keyword(s):  
Breast Cancer ◽  
Therapeutic Approaches ◽  
New Therapeutic Approaches

scholarly journals Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice

2019 ◽  
Vol 79 (06) ◽  
pp. 605-617 ◽  
Author(s):  
Andreas Schneeweiss ◽  
Carsten Denkert ◽  
Peter A. Fasching ◽  
Carlo Fremd ◽  
Oleg Gluz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Therapeutic Strategies ◽  
Routine Practice ◽  
Daily Routine ◽  
Therapeutic Approaches ◽  
New Therapeutic Approaches ◽  
Tumour Biology ◽  
Therapeutic Concepts

AbstractThe rapid increase in knowledge in tumour biology and tumour pathogenesis of triple-negative breast cancer (TNBC) has resulted in new therapeutic approaches and new therapeutic concepts for treatment. For years, TNBC has been considered to be a difficult-to-treat tumour due to its generally aggressive tumour biology and in view of limited therapeutic options. The risk of recurrence and metastasis is higher than in the case of other breast cancer subtypes of the same stage. In addition to surgery and radiation in the curative situation, systemic chemotherapy with anthracyclines and/or taxanes is still the therapy of choice. New therapeutic approaches are based on the knowledge that TNBC is a molecularly very heterogeneous disease. Research groups are working to classify TNBC better and better on a molecular level and use this molecular subtyping as the basis for new therapeutic strategies. The most promising new approaches and considerations regarding the therapy of TNBCs are shown below. In addition, the current therapeutic strategies are discussed using a fictitious case history, taking the current data and the resultant therapeutic consequence into account.

Triple negative breast cancer: new therapeutic approaches andBRCAstatus

Apmis ◽  
2018 ◽  
Vol 126 (5) ◽  
pp. 371-379 ◽  
Author(s):  
Gamze Guney Eskiler ◽  
Gulsah Cecener ◽  
Unal Egeli ◽  
Berrin Tunca
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Therapeutic Approaches ◽  
New Therapeutic Approaches

scholarly journals Recent advances in the medical treatment of breast cancer

F1000Research ◽  
2016 ◽  
Vol 5 ◽  
pp. 2786 ◽  
Author(s):  
Daniel A. Vorobiof
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Medical Treatment ◽  
Breast Cancer Treatment ◽  
Chemotherapeutic Drugs ◽  
Therapeutic Approaches ◽  
The Past ◽  
New Therapeutic Approaches ◽  
Receptor Modulator ◽  
Medical Oncologists

Over the past few decades, the systemic therapy of breast cancer (early and advanced) has changed considerably. For the past 40–50 years, and since the discovery and further therapeutic use of tamoxifen, a selective estrogen receptor modulator, breast cancer treatment has become the model for the development and success of tailored medical treatment. Much still needs to be done in improving outcomes for all patients with breast cancer, and especially for those who have advanced breast cancer, a challenging area for medical oncologists. Ongoing international clinical trials are currently evaluating new therapeutic approaches and identifying specific biological subsets that could determine a patient’s ability to respond to particular chemotherapeutic drugs.

scholarly journals Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer

Oncogene ◽  
2016 ◽  
Vol 36 (16) ◽  
pp. 2286-2296 ◽  
Author(s):  
A Harrod ◽  
J Fulton ◽  
V T M Nguyen ◽  
M Periyasamy ◽  
L Ramos-Garcia ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Therapeutic Approaches ◽  
New Therapeutic Approaches

scholarly journals Lupeol Impact on Breast Cancer Management

2021 ◽  
Vol 70 (1) ◽  
Author(s):  
Mirunalini S. ◽  
Susmitha R.
Keyword(s):  
Breast Cancer ◽  
Low Cost ◽  
Therapeutic Effects ◽  
Therapeutic Approaches ◽  
Cancer Management ◽  
New Therapeutic Approaches ◽  
Breast Cancer Model ◽  
Anti Cancer ◽  
Breast Cancer Management ◽  
Molecular Effects

Conventional therapies for the management of breast cancer are lacking in outcomes and also cause several adverse effects that prompted the acquisition of new therapeutic approaches for combating breast cancer without any of these pitfalls. Moreover, fostering a holistic therapeutic strategy might be a significant solution to this issue, because it is evident that products obtained via dietary sources have a great number of anti-breast cancer capacities with fewer side effects and low cost. Considerably over the past decade, the demand for triterpenes for breast cancer management has increased significantly due to the declining properties of cancer. However, lupeol (LUP) is a dietary triterpene and the active ingredient found in most medicinal plants has indeed been witnessed to manifest numerous pharmaceutical attributes especially anti-cancer activities, and is strongly related to the declining prevalence of breast cancer in Asian countries. Several reports offer valuable input into the lupeol mechanism of action and thereby propose that this was a multi-target substance with massive potential towards breast cancer (BC) by hitting pivotal molecular pathways associated with breast cancer. There seems to be extensive evidence of such a wonderful compound's anti-breast cancer activity. In this review, we strenuously reaffirm lupeol’s preventive and therapeutic effects in the breast cancer model, with a focus on multi-targeted biological and molecular effects.

Sign in / Sign up

Export Citation Format

Share Document